TSPYL2 and prostate cancer: For example, the expression levels of cancer-drivers/oncogenes MYC, MYB, and AR, whose roles in prostate cancer have been well established, were consistently lower in both TSPX-overexpressing LNCaP cells and TSPX-high clinical prostate cancer samples than the corresponding controls (Figure 5, and Supplementary Table 6).